Bevacizumab for the Treatment of Corneal Neovascularization
Status:
Unknown status
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to assess the efficacy and safety of the inhibitory
effect of bevacizumab (Avastin) with different routes including topical and subconjunctival
application on corneal neovascularization in the human eyes.